Additionally, a clinical trial investigating the use of CD33-directed CAR-T cells in patients with relapsed and refractory AML has reported promising outcomes in managing febrile syndromes, with significant fever reduction observed following a 12-hour administration of anti-TNF-α treatment30. Here, CD33 is linked to acute myeloid leukemia.